Just a little bit of useless information on an M&A between Biogen and Reata. What peaked my interest was that Biogen paid $7.3b for a company with earning potential of $1.5b in 2030 -
For Biogen, the deal gets the company’s hands on Skyclarys, which carries a sales potential of $1.5 billion in 2030, according to analysts.
Link to full article hereunder for anyone who is interested -
How Biogen outbid a rival 'large-cap' pharma to claim Reata for $7.3B | Fierce Pharma
Ann: Exceptional Results in Second Valve-in-Valve Case, page-38
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |